Saturday, October 3, 2026

USD/CNH Went Down By Over 4% In The Last 21 Sessions

ViaNews Editorial Team

February 20, 2023

USD/CNH Went Down By Over 4% In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 4.39% for the last 21 sessions. At 15:11 EST on Monday, 20 February, USD/CNH (USDCNH) is $6.86.

USD/CNH's yearly highs and lows, it's 0.085% up from its 52-week low and 0.36% down from its 52-week high.

News about

  • Eur/usd stays defensive around 1.0700 ahead of eurozone pmis, fed minutes. According to FXStreet on Sunday, 19 February, "Looking ahead, the risk-off mood may exert downside pressure on the EUR/USD pair amid a likely sluggish day. ", "A clear downside break of a three-month-old ascending trend line, now immediate resistance around 1.0730, keeps EUR/USD bears hopeful."
  • Eur/usd price analysis: remains pressured towards 1.0630-15 support area. According to FXStreet on Monday, 20 February, "Overall, EUR/USD is likely to decline further, even as the downside room appears limited.", "Following that, the 1.0600 and 1.0500 may entertain the EUR/USD sellers before directing them to the previous monthly low surrounding 1.0480. "
  • Eur/usd: hawkish set of FOMC minutes required to see a break towards 1.05 – ING. According to FXStreet on Monday, 20 February, "The Dollar rally might have come far enough for the time being and EUR/USD found good demand ahead of 1.06. ", "It will probably require quite a hawkish set of FOMC minutes on Wednesday for EUR/USD to break towards 1.05 - where we expect to see good demand ahead of a EUR/USD rally in the second quarter."
  • Eur/usd aims to recapture 1.0700 as risk appetite recovers, fed minutes in focus. According to FXStreet on Monday, 20 February, "The EUR/USD pair has attempted a recovery after dropping to near 1.0673 in the early European session. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com